Effects of thiamine and fenofibrate on high glucose and hypoxia-induced damage in cell models of the inner blood-retinal barrier

[1]  I. Čavar,et al.  Concentrations of Selected Cytokines and Vascular Endothelial Growth Factor in Aqueous Humor and Serum of Diabetic Patients , 2020, Seminars in ophthalmology.

[2]  M. Porta,et al.  Thiamine transporter 2 is involved in high glucose-induced damage and altered thiamine availability in cell models of diabetic retinopathy , 2019, Diabetes & vascular disease research.

[3]  A. Caccuri,et al.  Activation of retinal Müller cells in response to glucose variability , 2019, Endocrine.

[4]  M. Porta,et al.  Functional analysis of miR-21-3p, miR-30b-5p and miR-150-5p shuttled by extracellular vesicles from diabetic subjects reveals their association with diabetic retinopathy. , 2019, Experimental eye research.

[5]  M. S. Sajib,et al.  Role of Angiopoietin-2 in Vascular Physiology and Pathophysiology , 2019, Cells.

[6]  N. Luo,et al.  Association between ICAM-1 level and diabetic retinopathy: a review and meta-analysis , 2019, Postgraduate Medical Journal.

[7]  A. Keech,et al.  Fenofibrate Rescues Diabetes-Related Impairment of Ischemia-Mediated Angiogenesis by PPARα-Independent Modulation of Thioredoxin-Interacting Protein , 2019, Diabetes.

[8]  N. Lois,et al.  Fenofibrate for Diabetic Retinopathy , 2018, Asia-Pacific journal of ophthalmology.

[9]  Grazia Maugeri,et al.  NAP counteracts hyperglycemia/hypoxia induced retinal pigment epithelial barrier breakdown through modulation of HIFs and VEGF expression , 2018, Journal of cellular physiology.

[10]  A. Miyamoto,et al.  Beyond the Matrix: The Many Non-ECM Ligands for Integrins , 2018, International journal of molecular sciences.

[11]  S. Mohr,et al.  Müller cells and diabetic retinopathy , 2017, Vision Research.

[12]  Haitao Shen,et al.  Role of the PKCβII/JNK signaling pathway in acute glucose fluctuation-induced apoptosis of rat vascular endothelial cells , 2017, Acta Diabetologica.

[13]  Á. Valverde,et al.  Modulation of microglia in the retina: new insights into diabetic retinopathy , 2017, Acta Diabetologica.

[14]  P. Pasqualetti,et al.  Retinal neurodegeneration in patients with type 1 diabetes mellitus: the role of glycemic variability , 2017, Acta Diabetologica.

[15]  Alison L. Reynolds,et al.  Phenotype-based Discovery of 2-[(E)-2-(Quinolin-2-yl)vinyl]phenol as a Novel Regulator of Ocular Angiogenesis* , 2016, The Journal of Biological Chemistry.

[16]  R. Simó,et al.  Fenofibrate prevents the disruption of the outer blood retinal barrier through downregulation of NF-κB activity , 2016, Acta Diabetologica.

[17]  A. Paterson,et al.  Variation in SLC19A3 and Protection From Microvascular Damage in Type 1 Diabetes , 2015, Diabetes.

[18]  R. Simó,et al.  Beneficial effects of fenofibric acid on overexpression of extracellular matrix components, COX-2, and impairment of endothelial permeability associated with diabetic retinopathy. , 2015, Experimental eye research.

[19]  K. Alitalo,et al.  Endothelial destabilization by angiopoietin-2 via integrin β1 activation , 2015, Nature Communications.

[20]  M. Porta,et al.  Extracellular vesicles derived from mesenchymal stem cells induce features of diabetic retinopathy in vitro , 2014, Acta Diabetologica.

[21]  Elena Beltramo,et al.  Pericyte loss in diabetic retinopathy: mechanisms and consequences. , 2013, Current medicinal chemistry.

[22]  Jason Zastre,et al.  HIF1-α-mediated gene expression induced by vitamin B1 deficiency. , 2013, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition.

[23]  S. Abcouwer.  Direct Effects of PPARα Agonists on Retinal Inflammation and Angiogenesis May Explain How Fenofibrate Lowers Risk of Severe Proliferative Diabetic Retinopathy , 2012, Diabetes.

[24]  A. Keech,et al.  Therapeutic Effects of PPARα Agonists on Diabetic Retinopathy in Type 1 Diabetes Models , 2012, Diabetes.

[25]  Philippe Soriano,et al.  PDGFRβ signaling regulates mural cell plasticity and inhibits fat development. , 2011, Developmental cell.

[26]  R. Bischoff,et al.  Physiology and pathophysiology of matrix metalloproteases , 2010, Amino Acids.

[27]  Walter T Ambrosius,et al.  Effects of medical therapies on retinopathy progression in type 2 diabetes. , 2010, The New England journal of medicine.

[28]  Elena Berrone,et al.  Effects of high glucose and thiamine on the balance between matrix metalloproteinases and their tissue inhibitors in vascular cells , 2010, Acta Diabetologica.

[29]  Elena Berrone,et al.  Thiamine and benfotiamine prevent apoptosis induced by high glucose‐conditioned extracellular matrix in human retinal pericytes , 2009, Diabetes/metabolism research and reviews.

[30]  Elena Berrone,et al.  Different apoptotic responses of human and bovine pericytes to fluctuating glucose levels and protective role of thiamine , 2009, Diabetes/metabolism research and reviews.

[31]  H. Hammes,et al.  Establishment and characterization of a human retinal pericyte line: a novel tool for the study of diabetic retinopathy. , 2009, International journal of molecular medicine.

[32]  M. Porta,et al.  Effects of thiamine and benfotiamine on intracellular glucose metabolism and relevance in the prevention of diabetic complications , 2008, Acta Diabetologica.

[33]  P. Mitchell,et al.  Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial , 2007, The Lancet.

[34]  R. Babaei-Jadidi,et al.  High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease , 2007, Diabetologia.

[35]  Elena Berrone,et al.  Regulation of Intracellular Glucose and Polyol Pathway by Thiamine and Benfotiamine in Vascular Cells Cultured in High Glucose* , 2006, Journal of Biological Chemistry.

[36]  C. Betsholtz,et al.  Endothelial/Pericyte Interactions , 2005, Circulation research.

[37]  H. Hammes,et al.  Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. , 2004, Diabetes.

[38]  MarkusMeissner,et al.  PPARα Activators Inhibit Vascular Endothelial Growth Factor Receptor-2 Expression by Repressing Sp1-Dependent DNA Binding and Transactivation , 2004 .

[39]  C. Urbich,et al.  PPAR&agr; Activators Inhibit Vascular Endothelial Growth Factor Receptor-2 Expression by Repressing Sp1-Dependent DNA Binding and Transactivation , 2004, Circulation research.

[40]  L. Metheny-Barlow,et al.  The enigmatic role of angiopoietin-1 in tumor angiogenesis , 2003, Cell Research.

[41]  R. Babaei-Jadidi,et al.  Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. , 2003, Diabetes.

[42]  H. Hammes,et al.  Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy , 2003, Nature Medicine.

[43]  G. A. Limb,et al.  Differential expression of matrix metalloproteinases 2 and 9 by glial Müller cells: response to soluble and extracellular matrix-bound tumor necrosis factor-alpha. , 2002, The American journal of pathology.

[44]  G. A. Limb,et al.  In vitro characterization of a spontaneously immortalized human Müller cell line (MIO-M1). , 2002, Investigative ophthalmology & visual science.

[45]  K. Kashiwagi,et al.  MATRIX METALLOPROTEINASES IN HUMAN DIABETIC AND NONDIABETIC VITREOUS , 2001, Retina.

[46]  T. Nishikawa,et al.  The missing link: a single unifying mechanism for diabetic complications. , 2000, Kidney international. Supplement.

[47]  K. Suzuma,et al.  Hypoxia and Vascular Endothelial Growth Factor Selectively Up-regulate Angiopoietin-2 in Bovine Microvascular Endothelial Cells* , 1999, The Journal of Biological Chemistry.

[48]  M. Porta,et al.  Thiamine corrects delayed replication and decreases production of lactate and advanced glycation end-products in bovine retinal and human umbilical vein endothelial cells cultured under high glucose conditions , 1996, Diabetologia.